Search Results - "Brunner‐La Rocca, Hans Pieter"
-
1
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial
Published in European journal of heart failure (01-12-2020)“…ABSTRACT Aims EMPEROR‐Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction…”
Get full text
Journal Article -
2
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Published in Nature Medicine (01-12-2022)“…The EMPEROR-Preserved trial showed that the sodium–glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or…”
Get full text
Journal Article Magazine Article -
3
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
Published in European journal of heart failure (01-10-2019)“…Background The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial…”
Get full text
Journal Article -
4
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Published in European journal of heart failure (01-10-2019)“…Drugs that inhibit the sodium–glucose co‐transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2…”
Get full text
Journal Article -
5
Empagliflozin benefits in patients with heart failure and preserved ejection fraction
Published in Nature medicine (01-12-2022)“…Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection…”
Get full text
Journal Article